Ultimovacs Q3 2022: UV1’s moment of truth is drawing closer - Redeye

Redeye comments on Ultimovacs’ Q3 2022 report, as the company’s lead candidate is approaching its proverbial ‘moment of truth’ in the form of INITIUM and NIPU top-line data in H1 2023e. Further, we are encouraged by three-year overall survival data from cohort 1 of UV1-103 and are intrigued by biomarker data from the same trial that the company presented in October.

Länk till analysen i sin helhet: https://www.redeye.se/research/862660/ultimovacs-q3-2022-uv1s-moment-of-truth-is-drawing-closer?utm_source=finwire&utm_medium=RSS